Table of Contents
Advances in Hepatology
Volume 2015, Article ID 596829, 11 pages
http://dx.doi.org/10.1155/2015/596829
Review Article

Hepatitis B Virus Infection and the Kidney: Renal Abnormalities in HBV Patients, Antiviral Drugs Handling, and Specific Follow-Up

1Paris 6 University, Nephrology Department, Pitie-Salpetriere University Hospital, Paris 75013, France
2Liver Unit, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
3New Zealand Liver Transplant Unit, University of Auckland, Auckland 1010, New Zealand
4Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China
5Department of Medicine and Therapeutics, Institute of Digestive Disease and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
6Department of Internal Medicine and Medical Specialities (Di.Bi.M.I.S.), University of Palermo, 90133 Palermo, Italy
7NKC Institute of Gastroenterology and Hepatology, Prince of Songkla University, Songklanagarind Hospital, Hat Yai, Songkhla 90110, Thailand
8Paris 5 University, Inserm U-1016, Hepatology Department, Cochin University Hospital, Paris 75005, France

Received 1 September 2014; Accepted 4 February 2015

Academic Editor: Jose J. Marin

Copyright © 2015 Gilbert Deray et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Chronic hepatitis B virus (CHB) infection is one of the most common causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. Many patients with CHB have variable degrees of functional renal impairment, and approximately 2 to 15% of patients on hemodialysis have CHB. Several therapeutic regimens have been developed in the past years, among which oral nucleoside and nucleotide analogues have been demonstrated to be efficient and well tolerated. However, they all are excreted in the urine and may thus require dosage adjustment in patients with decreased renal function. Furthermore, a number of them may in addition be toxic to the kidneys, especially in those patients presenting with renal insufficiency.